Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02334280
Other study ID # InSHAPE Implementation Study
Secondary ID
Status Completed
Phase N/A
First received January 6, 2015
Last updated January 7, 2015
Start date September 2009
Est. completion date May 2013

Study information

Verified date January 2015
Source Dartmouth-Hitchcock Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardUnited States: Federal Government
Study type Interventional

Clinical Trial Summary

The goal of this project, which has not changed, is to evaluate the statewide implementation of a two-component intervention (health promotion plus academic detailing) with respect to consumer outcomes and changes in provider prescribing. The intervention, called In SHAPE, is delivered to people with serious mental illness (SMI) by two community mental health clinics (CMHCs). These CMHCs are compared to two CMHCs delivering usual-care to individuals with SMI. The specific aims of this study are:

1. Evaluate person-level and provider-level outcomes including: (a) consumer health behaviors, health indicators, mental health indicators, and acute health service utilization, (b) provider prescribing practices and program fidelity, and (c) program costs.

2. Evaluate system-level outcomes including: (a) consumer health behaviors and health indicators, (b) provider prescribing and program fidelity, and (c) acute services use.


Description:

Individuals with SMI die 10-25 years earlier than the general population and have disproportionately greater rates of medical comorbidity and disability associated with high rates of obesity, sedentary lifestyle, metabolic syndrome, and poor dietary habits. Despite greater costs and adverse outcomes associated with the combination of mental illness and poor physical health, little attention has been paid to the development of health promotion interventions designed to address the needs of the high-risk group of people with SMI. This natural experiment presents an unprecedented opportunity to evaluate the public health impact of a statewide health-promotion program for persons with SMI, a potential model for reducing early mortality among persons with SMI served by state mental-health systems nationwide.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date May 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Age 21 or older

- Serious mental illness defined by (a) an axis I diagnosis of major depression, bipolar disorder, schizoaffective disorder, or schizophrenia, (b) moderate impairment across multiple areas of psychological functioning, or (c) Global Assessment of Functioning (GAF) score less than 61

- Able to provide voluntary informed consent for participation in the study by the participant or by the participant's legally designated guardian or conservator

- Poor fitness as indicated by BMI > 25 or failure to adhere to the US Department of Health and Human Services Physical Activity Guidelines for Americans, i.e., at least 2.5 hr/week of moderate or 75 min/week of vigorous activity in more than one session

- Medical clearance for participation in an exercise and dietary modification program by a physician, physician assistant, or nurse practitioner

- An expressed willingness to participate in a diet and exercise program

- Currently taking an atypical antipsychotic medication

- Able to walk a city block

- Responsible for choice of foods and how they are prepared

Exclusion Criteria:

- Currently residing in a nursing home or group home

- Terminal physical illness expected to result in the death of the study subject within one year

- Primary diagnosis of dementia, co-morbid diagnosis of dementia, or significant cognitive impairment as indicated by a Mini-Mental State Examination (MMSE) score < 24

- Inability to speak and understand English

- Pregnancy

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research


Intervention

Behavioral:
In SHAPE
In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.

Locations

Country Name City State
United States West Central Behavioral Health Lebanon New Hampshire
United States Mental Health Center of Greater Manchester Manchester New Hampshire
United States Greater Nashua Mental Health Center at Community Council Nashua New Hampshire
United States Center for Life Management Salem New Hampshire

Sponsors (1)

Lead Sponsor Collaborator
Dartmouth-Hitchcock Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in exercise capacity Change in exercise capacity measured by the 6-minute walk test. baseline, 6-, 12-, and 24-months No
Secondary Self-reported physical activity Change in self-reported physical activity measured with International Physical Activity Questionnaire (IPAQ) baseline, 6-, 12-, and 24-months No
Secondary Change in dietary behaviors Change in dietary behaviors measured with the Block Food Frequency Questionnaire (FFQ)21 and the Questionnaire on Eating and Weight Patterns (QEWP). baseline, 6-, 12-, and 24-months No
Secondary Change in stage of change Change in stage of change measured with the Weight Loss Behavior-Stage of Change Scale (WLB-SOC) 23 to assess stage of change for engaging in healthy eating and exercise behaviors. baseline, 6-, 12-, and 24-months No
Secondary Change in eating behavior Change in eating behavior measured with the Dutch Eating Behavior Questionnaire which includes 13 questions assessing emotional eating and 10 questions related to external eating behaviors baseline, 6-, 12-, and 24-months No
Secondary Change in physical measurement Including height, weight, pulse, CO2 level, lung capacity from spirometer, variables from impedance measure such as percentage of body fat and percentage of lean muscle mass, cholesterol and triglyceride levels from finger stick (cholesterol data for data points that have already passed will be collected from participants' clinic and hospital records), waist circumference: BMI derived from height and weight. baseline, 6-, 12-, and 24-months No
Secondary Change in smoking and substance use Change in smoking and substance use measured by questions developed for R01DA021245, "Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia," and questions from the "Quit Smoking Decision Aid"( developed by Ferron and Brunette, CPHS # 180) to ascertain smoking frequency, quantity, and cessation attempts baseline, 6-, 12-, and 24-months No
Secondary Change in psychological functioning (depression, negative symptoms, and self-efficacy). Change in psychological functioning measured by the Center for Epidemiologic Studies Depression Scale,Scale to Assess Negative Symptoms,16 and the Self-Rated Abilities for Health Practices Scale will be used to assess these constructs. baseline, 6-, 12-, and 24-months No
Secondary Change in social functioning Change in social functioning measured by the Social Network Questionnaire and Lehman Social Contact Scale. baseline, 6-, 12-, and 24-months No
Secondary Change in family contact Change in family contact measured by the Revised Family Contact Questionnaire. baseline, 6-, 12-, and 24-months No
Secondary Change in social support and eating habits Change in the impact of social support on eating habits measured by the Social Support and Eating Habits Survey baseline, 6-, 12-, and 24-months No
Secondary Change in social support and exercise Change in the impact of social support on exercise behaviors measured by the Social Support and Exercise Survey baseline, 6-, 12-, and 24-months No
Secondary Change in comorbid medical illness Change in comorbid medical illness measured using a medical problems list. baseline, 6-, 12-, and 24-months No
Secondary Change in medications Change in medications measured by gathering information from participants about type, dose, and frequency of all prescribed medications. baseline, 6-, 12-, and 24-months No
Secondary Change in service use Measured change in service use based on a measured designed for the In SHAPE studies to collect self-reported use of emergency services and hospitalizations. baseline, 6-, 12-, and 24-months No
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A